ArticleBreast cancer (Tokyo, Japan)2026
Evaluation of serum microRNA-9-5p expression and its predicted target genes as potential biomarkers for breast cancer.
Article in Breast cancer (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer (BC) is a complex genetic disorder and a major global health concern among women. The rising incidence of BC highlights the need for reliable molecular biomarkers to enable early diagnosis, monitor disease progression, and guide therapeutic interventions. MicroRNAs (miRNAs) have emerged as promising candidates due to their key regulatory roles in gene expression and their diagnostic and prognostic potential.
methodsIn this study, serum miR-9-5p expression was evaluated in 100 BC patients and 100 healthy controls using quantitative real-time PCR (qPCR). Potential target genes of hsa-miR-9-5p were predicted using the miRDB database and ranked according to interaction scores.
resultsSerum miR-9-5p was significantly upregulated in BC patients compared with healthy controls (P-value < 0.0001).
conclusionThe marked elevation of serum miR-9-5p in BC patients suggests its possibility potential as a non-invasive biomarker for early detection. The predicted target genes warrant further functional validation to clarify the molecular mechanisms underlying hsa-miR-9-5p-mediated regulation in breast cancer. Independent cohort studies are recommended to confirm these findings and further explore their clinical utility.
Indexed as
Identifiers
42213364What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.